70 participants
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2026-06-22
- Start Date:
- 2023-01-18
- Completion:
- 2027-12-01
Conditions
- Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
- Alopecia Areata
Interventions
- DRUG
No Results Yet